• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of amjphAmerican Journal of Public Health Web SiteAmerican Public Health Association Web SiteSubmissionsSubscriptionsAbout Us
Am J Public Health. 1985 July; 75(7): 739–744.
PMCID: PMC1646302

Benefits, risks and costs of immunization for measles, mumps and rubella.

Abstract

For a single year, 1983, we compared the actual and estimated morbidity, mortality, and costs attributable to measles, mumps, and rubella with having or not having a childhood immunization program using the combined measles-mumps-rubella (MMR) vaccine. Without an immunization program, an estimated 3,325,000 cases of measles would occur as compared to 2,872 actual cases in 1983 with a program. Instead of an expected 1.5 million rubella cases annually, there were only 3,816 actual cases. Mumps cases were lowered from an expected 2.1 million to 32,850 actual cases. Comparable reductions in disease-associated complications, sequelae, and deaths are gained with an immunization program. Without a vaccination program, disease costs would have been almost $1.4 billion. Based on the actual incidence of disease in 1983, costs were estimated to be approximately +14.5 million. Expenditures for immunization, including vaccine administration costs and the costs associated with vaccine reactions, totaled $96 million. The resulting benefit-cost ratio for the MMR immunization program is approximately 14:1. The savings realized due to the use of combination rather than single antigen vaccine total nearly $60 million.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1008K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Witte JJ, Axnick NW. The benefits from 10 years of measles immunization in the United States. Public Health Rep. 1975 May-Jun;90(3):205–207. [PMC free article] [PubMed]
  • Albritton RB. Cost-benefits of measles eradication: effects of a federal intervention. Policy Anal. 1978 Winter;4(1):1–21. [PubMed]
  • Schoenbaum SC, Hyde JN Jr Bartoshesky L, Crampton K. Benefit-cost analysis of rubella vaccination policy. N Engl J Med. 1976 Feb 5;294(6):306–310. [PubMed]
  • Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. Am J Dis Child. 1982 Apr;136(4):362–364. [PubMed]
  • LANGMUIR AD. Medical importance of measles. Am J Dis Child. 1962 Mar;103:224–226. [PubMed]
  • Nolan TF, Jr, Goodman RA, Patriarca PA, Hinman AR. Hospitalizations for measles, 1970-78. Am J Public Health. 1982 Sep;72(9):1037–1039. [PMC free article] [PubMed]
  • Modlin JF, Jabbour JT, Witte JJ, Halsey NA. Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics. 1977 Apr;59(4):505–512. [PubMed]
  • Axnick NW, Shavell SM, Witte JJ. Benefits due to immunization against measles. Public Health Rep. 1969 Aug;84(8):673–680. [PMC free article] [PubMed]
  • Koplan JP, Axnick NW. Benefits, risks and costs of viral vaccines. Prog Med Virol. 1982;28:180–191. [PubMed]
  • Buynak EB, Weibel RE, Whitman JE, Jr, Stokes J, Jr, Hilleman MR. Combined live measles, mumps, and rubella virus vaccines. JAMA. 1969 Mar 24;207(12):2259–2262. [PubMed]
  • Lerman SJ, Bollinger M, Brunken JM. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics. 1981 Jul;68(1):18–22. [PubMed]
  • Weibel RE, Buynak EB, McLean AA, Roehm RR, Hilleman MR. Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines. Proc Soc Exp Biol Med. 1980 Nov;165(2):260–263. [PubMed]
  • Krugman S, Muriel G, Fontana VJ. Combined live measles, mumps, rubella vaccine. Immunological response. Am J Dis Child. 1971 May;121(5):380–381. [PubMed]
  • Schwarz AJ, Jackson JE, Ehrenkranz NJ, Ventura A, Schiff GM, Walters VW. Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. Am J Dis Child. 1975 Dec;129(12):1408–1412. [PubMed]
  • Krugman RD, Witte JJ, Parkman PD, Herrmann KL, Meyer HM, Jr, Wende RD, Meyer BC, Dungca R. Combined administration of measles, mumps, rubella, and trivalent oral poliovirus vaccines. Public Health Rep. 1977 May-Jun;92(3):220–222. [PMC free article] [PubMed]
  • Preblud SR, Serdula MK, Frank JA, Jr, Brandling-Bennett AD, Hinman AR. Rubella vaccination in the United States: a ten-year review. Epidemiol Rev. 1980;2:171–194. [PubMed]
  • Landefeld JS, Seskin EP. The economic value of life: linking theory to practice. Am J Public Health. 1982 Jun;72(6):555–566. [PMC free article] [PubMed]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...